ECSP099091A - Profarmaco de compuesto de cinamida - Google Patents

Profarmaco de compuesto de cinamida

Info

Publication number
ECSP099091A
ECSP099091A EC2009009091A ECSP099091A ECSP099091A EC SP099091 A ECSP099091 A EC SP099091A EC 2009009091 A EC2009009091 A EC 2009009091A EC SP099091 A ECSP099091 A EC SP099091A EC SP099091 A ECSP099091 A EC SP099091A
Authority
EC
Ecuador
Prior art keywords
profarmaco
formula
cinamide
compound
cinamide compound
Prior art date
Application number
EC2009009091A
Other languages
English (en)
Inventor
Teiji Kimura
Koki Kawano
Noritaka Kitazawa
Mamoru Takaishi
Koichi Ito
Toshihiko Kaneko
Nobuaki Sato
Ikuo Kushida
Original Assignee
Eisai R & D Mananagement Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R & D Mananagement Co Ltd filed Critical Eisai R & D Mananagement Co Ltd
Publication of ECSP099091A publication Critical patent/ECSP099091A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Cultivation Of Plants (AREA)
  • Seasonings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La descripción es un profármaco óptimo de un compuesto de cinamida representado por la fórmula (I) a continuación. En la fórmula, Ra y Rb respectivamente representan un grupo alquilo C1-6 o los similares; Xa representa un grupo metoxi o un átomo de flúor; Y representa un grupo fosfono o los similares; y A representa un derivado de lactama cíclico.
EC2009009091A 2006-07-28 2009-01-27 Profarmaco de compuesto de cinamida ECSP099091A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82076106P 2006-07-28 2006-07-28
JP2006206007 2006-07-28
US86925906P 2006-12-08 2006-12-08
JP2006331274 2006-12-08

Publications (1)

Publication Number Publication Date
ECSP099091A true ECSP099091A (es) 2009-02-27

Family

ID=38981524

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009091A ECSP099091A (es) 2006-07-28 2009-01-27 Profarmaco de compuesto de cinamida

Country Status (25)

Country Link
US (1) US7737141B2 (es)
EP (1) EP2048143A4 (es)
JP (1) JPWO2008013213A1 (es)
KR (1) KR20090033910A (es)
AR (1) AR062095A1 (es)
AU (1) AU2007277729A1 (es)
CA (1) CA2658037A1 (es)
CO (1) CO6150153A2 (es)
CR (1) CR10499A (es)
EA (1) EA200970172A1 (es)
EC (1) ECSP099091A (es)
GE (1) GEP20115176B (es)
HN (1) HN2009000157A (es)
IL (1) IL196351A0 (es)
MA (1) MA30636B1 (es)
MX (1) MX2008015504A (es)
MY (1) MY144971A (es)
NO (1) NO20090541L (es)
NZ (1) NZ574102A (es)
PE (1) PE20080281A1 (es)
SA (1) SA07280403B1 (es)
SV (1) SV2009003157A (es)
TN (1) TN2009000024A1 (es)
TW (1) TW200821319A (es)
WO (1) WO2008013213A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2566094A1 (en) * 2004-05-26 2005-12-08 Eisai R & D Management Co., Ltd. Cinnamide compound
AU2005297966B2 (en) * 2004-10-26 2010-12-23 Eisai R & D Management Co., Ltd. Amorphous object of cinnamide compound
EP1953151A4 (en) * 2005-11-18 2010-06-02 Eisai R&D Man Co Ltd SALTS FROM A CYNNAMIDE COMPOUND OR SOLVATE THEREOF
CN101309916A (zh) * 2005-11-18 2008-11-19 卫材R&D管理有限公司 制备肉桂酰胺衍生物的方法
BRPI0618814A2 (pt) * 2005-11-24 2014-04-29 Eisai R&D Man Co Ltd Composto ou um sal farmacologicamente aceitável do mesmo, e, agente farmacêutico
TWI370130B (en) * 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
US7737141B2 (en) 2006-07-28 2010-06-15 Eisai R&D Management Co., Ltd. Prodrug of cinnamide compound
CL2008000582A1 (es) * 2007-02-28 2008-06-27 Eisai R&D Man Co Ltd Compuestos ciclicos derivados de oximorfolina condensados; farmacos que comprenden a dichos compuestos; y su uso para tratar enfermedad de alzheimer, demencia senil, sindrome de down o amiloidosis.
WO2008140111A1 (ja) * 2007-05-16 2008-11-20 Eisai R & D Management Co., Ltd. シンナミド誘導体のワンポット製造方法
CA2694401C (en) 2007-08-31 2012-12-04 Eisai R&D Management Co., Ltd. Polycyclic compound
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
US8217064B2 (en) 2007-12-20 2012-07-10 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
WO2009080533A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
WO2009087127A1 (en) 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Modulators for amyloid beta
WO2009096349A1 (ja) * 2008-01-28 2009-08-06 Eisai R & D Management Co., Ltd. 結晶性のシンナミド化合物またはその塩
KR101247840B1 (ko) 2008-02-22 2013-03-26 에프. 호프만-라 로슈 아게 아밀로이드 베타 조절제
JP5502089B2 (ja) 2008-10-09 2014-05-28 エフ．ホフマン−ラ ロシュ アーゲー アミロイドβのモジュレーター
WO2010052199A1 (en) 2008-11-10 2010-05-14 F. Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
CN103080079B (zh) * 2010-07-02 2015-01-21 比皮艾思药物研发有限公司 苯基氨基甲酸酯化合物及含有苯基氨基甲酸酯化合物的肌肉松弛剂
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
CN103282346B (zh) 2011-01-13 2014-11-19 比皮艾思药物研发有限公司 用于制备苯基氨基甲酸酯衍生物的方法
ES2555872T3 (es) 2011-06-15 2016-01-11 Basf Se Poliésteres ramificados con grupos sulfonato
US8901066B2 (en) 2011-06-15 2014-12-02 Basf Se Branched polyesters with sulfonate groups
EP2797879B1 (en) 2011-12-27 2018-12-26 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain
US9907776B2 (en) * 2013-03-12 2018-03-06 Bio-Pharm Solutions, Co., Ltd. Phenyl carbamate compound and a composition for preventing or treating a psychiatric disorder comprising the same
ES2998534T3 (en) 2013-03-12 2025-02-20 Bio Pharm Solutions Co Ltd Phenyl carbamate compounds for use in preventing or treating pediatric epilesy
HUE058802T2 (hu) * 2016-12-09 2022-09-28 Denali Therapeutics Inc RIPK1 inhibitorokként alkalmas vegyületek
CN110143935B (zh) * 2019-06-03 2022-09-30 华侨大学 一种2，5-二取代呋喃衍生物的制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0219756B1 (de) 1985-10-09 1994-01-05 Shell Internationale Researchmaatschappij B.V. Neue Acrylsäureamide
DE3541716A1 (de) 1985-11-26 1987-05-27 Celamerck Gmbh & Co Kg Neue acrylsaeureamide
JPH03206042A (ja) 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
WO1991012237A1 (en) 1990-02-08 1991-08-22 Eisai Co., Ltd. Benzenesulfonamide derivative
JPH05194517A (ja) 1992-01-16 1993-08-03 Tanabe Seiyaku Co Ltd ６−メルカプトプリン誘導体及びその製法
AU680870B2 (en) * 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
EP0784612A1 (en) 1994-10-04 1997-07-23 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
JPH08283219A (ja) 1995-04-07 1996-10-29 Eisai Co Ltd アラルキルアミノアルキルアミド誘導体
EE9800390A (et) * 1996-05-10 1999-06-15 Icos Corporation Karboliini derivaadid
JP2000515153A (ja) 1996-07-22 2000-11-14 モンサント カンパニー チオールスルホンアミド メタロプロテアーゼインヒビター
WO1998024785A1 (en) 1996-12-02 1998-06-11 Fujisawa Pharmaceutical Co., Ltd. Indole-urea derivatives with 5-ht antagonist properties
JP3108997B2 (ja) 1997-03-31 2000-11-13 武田薬品工業株式会社 アゾール化合物、その製造法および用途
AU6520098A (en) 1997-03-31 1998-10-22 Takeda Chemical Industries Ltd. Azole compounds, their production and their use
JP2001527083A (ja) 1997-12-31 2001-12-25 ザ・ユニバーシティ・オブ・カンザス 第二級および第三級アミン含有薬剤の水溶性プロドラッグおよびその製造方法
GB9816984D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US6235728B1 (en) * 1999-02-19 2001-05-22 Bristol-Myers Squibb Company Water-soluble prodrugs of azole compounds
EP1159263A1 (en) 1999-02-26 2001-12-05 Merck & Co., Inc. Novel sulfonamide compounds and uses thereof
AU2899400A (en) 1999-03-04 2000-09-21 Nortran Pharmaceuticals Inc. Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics
WO2001068585A1 (en) 2000-03-14 2001-09-20 Fujisawa Pharmaceutical Co., Ltd. Novel amide compounds
US20010051642A1 (en) * 2000-04-17 2001-12-13 Kyunghye Ahn Method for treating Alzheimer's disease
WO2001081312A2 (en) 2000-04-24 2001-11-01 Merck Frosst Canada & Co. Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
ATE288898T1 (de) * 2000-12-04 2005-02-15 Hoffmann La Roche Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten
GB0108770D0 (en) * 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
AU2002364549B2 (en) 2001-12-10 2007-11-22 Amgen, Inc Vanilloid receptor ligands and their use in treatments
GEP20063920B (en) * 2001-12-20 2006-09-11 Bristol Myers Squibb Co Alpha-(n-sulphonamido) acetamide derivatives as beta-amyloid inhibitors
JP2003206280A (ja) 2001-12-28 2003-07-22 Takeda Chem Ind Ltd ビアリール化合物およびその用途
DE10211101A1 (de) 2002-03-14 2003-09-25 Basf Ag Katalysatoren und Verfahren zur Herstellung von Aminen
GB0207436D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
JP2005531574A (ja) * 2002-05-22 2005-10-20 アムジエン・インコーポレーテツド 痛みの治療にバニロイド受容体リガンドとして使用するためのアミノ−ピリジン、−ピリジンおよびピリダジン誘導体
SI1511710T1 (sl) 2002-05-31 2014-04-30 Proteotech, Inc. Spojine, sestavki in postopki za zdravljenje amiloidnih bolezni in sinukleinopatij, kot je Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsova bolezen
DE50312261D1 (de) * 2002-07-12 2010-02-04 Sanofi Aventis Deutschland Heterozyklisch substituierte benzoylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US6900354B2 (en) 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
CN1747936A (zh) * 2003-02-12 2006-03-15 特兰斯泰克制药公司 作为治疗试剂的取代吡咯衍生物
EP1628666B1 (en) * 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
CA2536954C (en) * 2003-08-29 2012-11-27 Exelixis, Inc. C-kit modulators and methods of use
BRPI0417267A (pt) 2003-12-22 2007-04-17 Pfizer derivados de triazol como antagonistas de vasopressina
NZ548208A (en) * 2004-02-12 2010-09-30 Transtech Pharma Inc Substituted azole derivatives, compositions, and methods of use
CA2566094A1 (en) 2004-05-26 2005-12-08 Eisai R & D Management Co., Ltd. Cinnamide compound
AU2005297966B2 (en) 2004-10-26 2010-12-23 Eisai R & D Management Co., Ltd. Amorphous object of cinnamide compound
US20060241038A1 (en) 2005-04-20 2006-10-26 Eisai Co., Ltd. Therapeutic agent for Abeta related disorders
WO2007034282A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
CN101309916A (zh) * 2005-11-18 2008-11-19 卫材R&D管理有限公司 制备肉桂酰胺衍生物的方法
EP1953151A4 (en) 2005-11-18 2010-06-02 Eisai R&D Man Co Ltd SALTS FROM A CYNNAMIDE COMPOUND OR SOLVATE THEREOF
BRPI0618814A2 (pt) 2005-11-24 2014-04-29 Eisai R&D Man Co Ltd Composto ou um sal farmacologicamente aceitável do mesmo, e, agente farmacêutico
TWI370130B (en) * 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
US20070117839A1 (en) * 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
PL1992618T3 (pl) 2006-03-09 2012-06-29 Eisai R&D Man Co Ltd Policykliczna pochodna cynamidowa
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
US7737141B2 (en) 2006-07-28 2010-06-15 Eisai R&D Management Co., Ltd. Prodrug of cinnamide compound
CA2677296A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
WO2008137139A1 (en) 2007-05-07 2008-11-13 Schering Corporation Gamma secretase modulators
DE602008004769D1 (en) * 2007-05-11 2011-03-10 Hoffmann La Roche Hetarylaniline als modulatoren für amyloid beta
US8242150B2 (en) 2007-06-13 2012-08-14 Merck Sharp & Dohme Corp. Triazole derivatives for treating alzheimer'S disease and related conditions
PE20090957A1 (es) 2007-08-06 2009-07-13 Schering Corp Moduladores de gamma secretasa

Also Published As

Publication number Publication date
US20090048213A1 (en) 2009-02-19
SV2009003157A (es) 2010-01-12
PE20080281A1 (es) 2008-05-05
AR062095A1 (es) 2008-10-15
JPWO2008013213A1 (ja) 2009-12-17
IL196351A0 (en) 2009-09-22
AU2007277729A1 (en) 2008-01-31
MA30636B1 (fr) 2009-08-03
NZ574102A (en) 2010-10-29
US7737141B2 (en) 2010-06-15
GEP20115176B (en) 2011-03-10
NO20090541L (no) 2009-02-03
CR10499A (es) 2009-03-20
MX2008015504A (es) 2008-12-18
EP2048143A4 (en) 2010-11-03
EA200970172A1 (ru) 2009-08-28
HN2009000157A (es) 2011-01-24
CA2658037A1 (en) 2008-01-31
TN2009000024A1 (en) 2010-08-19
WO2008013213A1 (en) 2008-01-31
MY144971A (en) 2011-11-30
TW200821319A (en) 2008-05-16
EP2048143A1 (en) 2009-04-15
KR20090033910A (ko) 2009-04-06
SA07280403B1 (ar) 2010-12-01
CO6150153A2 (es) 2010-04-20

Similar Documents

Publication Publication Date Title
ECSP099091A (es) Profarmaco de compuesto de cinamida
CY1112705T1 (el) Συντηγμενες κυκλικες ενωσεις
CY1111671T1 (el) Ετεροκυκλικη ενωση
MA32956B1 (fr) Derives de 5-amino-2-(1-hydroxyethyl)-tetrahydropyrane
CR9830A (es) Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la b-secretasa
EA201170096A1 (ru) Замещенные производные пиримидона
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
EA201070246A1 (ru) Циклические аминные соединения
HRP20120323T1 (en) Diarylhydantoin compounds
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
UY28290A1 (es) Compuestos farmacéuticos novedosos
CR8827A (es) Compuesto heterociclico fusionado
NO20084583L (no) Makrosykliske kinase-inhibitorer
CY1113716T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
EA200970372A1 (ru) Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
DK1954264T3 (da) Fremgangsmåde til fremstilling af epoxybutanol-mellemprodukter
CR11463A (es) Compuestos de piridilmetil-sulfonamida
MY149400A (en) Bridged six-membered ring compounds
EA201170595A1 (ru) ПРОИЗВОДНОЕ ФЕНАНТРОИНДОЛИЗИДИНА И ИНГИБИТОР NFkB, СОДЕРЖАЩИЙ ЕГО В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА
EA201170596A1 (ru) ФЕНАНТРОИНДОЛИЗИДИНОВОЕ СОЕДИНЕНИЕ И ИНГИБИТОР NFkB, СОДЕРЖАЩИЙ ЕГО В КАЧЕСТВЕ ДЕЙСТВУЮЩЕГО ИНГРЕДИЕНТА
EA201071424A1 (ru) Сульфонатные соли 2-амино-3-карбэтоксиамино-6-(4-фторбензиламино)пиридина
CY1111573T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
ECSP11011081A (es) 3-aminociclopentancarboxamidas